目的 探究門(mén)冬胰島素在治療糖尿病腎?。―N）中的療效及其對(duì)患者超氧化物歧化酶（SOD）及丙二醛（MDA）的影響。方法 選取2015年1月-2016年1月于青海省交通醫(yī)院收治的96例DN患者，按照隨機(jī)數(shù)字表法均分為實(shí)驗(yàn)組和對(duì)照組，每組48例，對(duì)照組患者給予皮下注射合成人胰島素進(jìn)行治療，實(shí)驗(yàn)組給予皮下注射門(mén)冬胰島素，在治療1、3、5 d測(cè)定兩組空腹血糖（FPG）及餐后2 h血糖（2hPG）并對(duì)比，在治療第5天對(duì)兩組24 h尿微量白蛋白排泄率（UAER）及內(nèi)生肌酐清除率（Ccr）進(jìn)行測(cè)定對(duì)比，而后對(duì)兩組治療前后SOD及MDA水平進(jìn)行測(cè)定并對(duì)比。結(jié)果 經(jīng)治療，兩組在治療1、3、5 d后的FPG及2hPG均低于治療前，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；實(shí)驗(yàn)組在治療第3、5天時(shí)的FPG及2hPG均低于對(duì)照組，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療5 d后測(cè)量結(jié)果顯示，兩組UAER水平均明顯降低，Ccr水平明顯升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；實(shí)驗(yàn)組UAER水平顯著低于對(duì)照組，Ccr水平高于對(duì)照組，兩組差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療前兩組SOD及MDA水平差異不具有統(tǒng)計(jì)學(xué)意義；治療后，兩組SOD水平均顯著升高，MDA水平均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；實(shí)驗(yàn)組的SOD水平顯著高于對(duì)照組，MDA水平顯著低于對(duì)照組，組間差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 門(mén)冬胰島素在治療糖尿病腎病方面效果肯定，同時(shí)該藥能夠提高糖尿病腎病患者SOD、降低MDA水平，對(duì)患者的治療具有積極意義。

Objective To investigate the efficacy of insulin aspart in the treatment of diabetic nephropathy (DN) and its effects on superoxide dismutase (SOD) and malondialdehyde (MDA). Methods 96 patients with DN who were admitted to our hospital from January 2015 to January 2016 were randomly divided into experimental group and control group according to random number table method, 48 cases in each group. Patients in control group were given hypodermic injection of synthetic insulin The rats in experimental group were injected subcutaneously with insulin aspart, the fasting blood glucose (FPG) and 2h postprandial blood glucose (2hPG) were measured at 1, 3 and 5 days after treatment. The blood glucose of 24 h urine microalbumin (UAER) and endogenous creatinine clearance (Ccr) were measured and compared, and then the two groups before and after treatment SOD and MDA levels were measured and compared. Results The 1, 3, 5 d FPG and 2 h PG in the experimental group were lower than those in the control group after treatment (P<0.05), but there was no significant difference between the two groups before treatment. The level of UAER in the 5th day after treatment was significantly lower than that in the control group, and the Ccr was higher than that in the control group (P<0.05). There was no significant difference in SOD and MDA levels between the two groups before treatment. The SOD level in the 5th day after treatment was significantly higher than that in the control group, the MDA level was significantly lower than that in the control group (P<0.05). Conclusions Aspart insulin in the treatment of diabetic nephropathy is worthy of affirmation. At the same time, this medicine can improve the level of SOD in patients with diabetic nephropathy, and has positive significance for the treatment of patients.